Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-Enenitrile
Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
1 - 42 . (canceled)
43 . A process for preparing a modified release solid oral dosage form comprising a core composition, a sub-coating layer coating the core composition, and an enteric coating layer encapsulating the sub-coating layer and the core composition, the process comprising the steps of:
(a) preparing a core tablet comparing the core composition by:
(i) combining an (E) isomer, a (Z) isomer, a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile, (S)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile, or a mixture of (R) and(S) isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile (Compound I) having the structure:
where *C is a stereochemical center, or a pharmaceutically acceptable salt thereof, with microcrystalline cellulose, mannitol, and hydroxypropyl methyl cellulose;
(ii) mechanically mixing the combination of Compound (I) or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, mannitol, and hydroxypropyl methyl cellulose;
(iii) transferring a crosslinked homopolymer of N-vinyl-2-pyrrolidone and sodium stearyl fumarate to the combination of Compound (I) or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, mannitol, and hydroxypropyl methyl cellulose;
(iv) mechanically mixing the combination of Compound (I) or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, mannitol, hydroxypropyl methyl cellulose, crosslinked homopolymer of N-vinyl-2-pyrrolidone, and sodium stearyl fumarate to provide a core tablet blend; and
(v) compressing the core tablet blend with a tablet press to provide the core tablet;
(b) preparing a sub-coated core tablet by:
(vi) stirring a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose with water to form a sub-coating suspension;
(vii) applying the sub-coating suspension to the core tablet to provide a sub-coated core tablet; and
(c) encapsulating the sub-coated core tablet with an enteric coating layer by:
(viii) stirring at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone with water to form an enteric coating suspension;
(ix) applying the enteric coating suspension to the sub-coated core tablet to provide the modified release solid oral dosage form;
wherein the modified release solid oral dosage form comprises by weight:
about 6% to about 20% of the Compound (I) or a pharmaceutically acceptable salt thereof,
about 34% to about 72% of microcrystalline cellulose,
about 5% to about 25% mannitol,
about 0% to about 20% of hydroxypropyl methyl cellulose,
about 0.5% to about 1.5% of crosslinked homopolymer of N-vinyl-2-pyrrolidone, and about 0.5% to about 1.5% of sodium stearyl fumarate.
44 . The process of claim 43 , wherein the cellulose derivative is selected from cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose, hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose succinate (HPMCS), and hydroxypropylmethylcellulose acetate succinate (HPMCAS).
45 . The process of claim 43 , wherein:
the sub-coating layer comprises a polyvinyl alcohol; and
the enteric coating layer comprises a poly(methacrylic acid-co-ethyl acrylate) copolymer.
46 . The process of claim 45 , wherein the polyvinyl alcohol is a pigmented polyvinyl alcohol.
47 . The process of claim 43 , wherein:
the modified release solid oral dosage form releases less than about 10% by weight of Compound (I) or a pharmaceutically acceptable salt thereof in less than two hours at a pH less than or equal to about 2.0;
at least about 80% by weight of Compound (I) or a pharmaceutically acceptable salt thereof in about 15 minutes to about two hours at a pH equal to or more than about 6.0; and
any unreleased amount of Compound (I) is released by the end of about 7.5 hours at a pH equal to or more than about 6.0.
48 . The process of claim 43 , wherein the core composition comprises Compound (I).
49 . The process of claim 43 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is an (E) and (Z) mixture of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile.
50 . The process of claim 43 , wherein at least about 85% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer.
51 . The process of claim 43 , wherein at least about 90% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer.
52 . The process of claim 43 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is a substantially pure amorphous form.
53 . The process of claim 43 , wherein the core composition comprises about 30 mg to about 100 mg of Compound (I) or a pharmaceutically acceptable salt thereof.
54 . The process of claim 43 , wherein the core composition further comprises at least one excipient selected from fillers, drug release modifiers, disintegrants, and lubricants.
55 . The process of claim 43 , wherein the core composition weighs about 83% to about 91% of the total weight of the modified release solid oral dosage form.
56 . The process of claim 43 , wherein the sub-coating layer weighs about 2% to about 4% by weight of the modified release solid oral dosage form.
57 . The process of claim 43 , wherein the enteric coating layer further comprises a solubilizer and a plasticizer/anti-tacking agent.
58 . The process of claim 43 , wherein the enteric coating layer weighs about 6% to about 20% of the total weight of the modified release solid oral dosage form.
59 . The process of claim 43 , wherein the enteric coating layer comprises by total weight of the modified release solid oral dosage form:
about 5% to about 16% of EUDRAGIT® L 30 D-55 or EUDRAGIT® L 100-55;
about 1% to about 3% of PlasACRYL™ T20; and
about 0.3% to about 0.8% of Polysorbate 80.
60 . The process of claim 43 , wherein the core composition weighs about 80% to about 91% of the total weight of the modified release solid oral dosage form.
61 . A process for preparing a modified release solid oral dosage form comprising a core composition, a sub-coating layer coating the core composition, and an enteric coating layer encapsulating the sub-coating layer and the core composition, the process comprising the steps of:
(a) preparing a core tablet by:
(i) combining a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile, (S)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl] piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile (Compound I) having the structure:
where *C is a stereochemical center, or a pharmaceutically acceptable salt thereof, with microcrystalline cellulose, mannitol, and hydroxypropyl methyl cellulose;
(ii) mechanically mixing the combination of Compound (I) or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, mannitol, and hydroxypropyl methyl cellulose;
(iii) transferring a crosslinked homopolymer of N-vinyl-2-pyrrolidone and sodium stearyl fumarate to the combination of Compound (I) or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, mannitol, and hydroxypropyl methyl cellulose;
(iv) mechanically mixing the combination of Compound (I) or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, mannitol, hydroxypropyl methyl cellulose, crosslinked homopolymer of N-vinyl-2-pyrrolidone, and sodium stearyl fumarate to provide a core tablet blend; and
(v) compressing the core tablet blend with a tablet press to provide the core tablet;
(b) preparing a sub-coated core tablet by:
(vi) stirring a polyvinyl alcohol with water to form a sub-coating suspension;
(vii) applying the sub-coating suspension to the core tablet to provide a sub-coated core tablet; and
(c) encapsulating the sub-coated core tablet with an enteric coating layer by:
(viii) stirring a poly(methacrylic acid-co-ethyl acrylate) copolymer with water to form an enteric coating suspension;
(ix) applying the enteric coating suspension to the sub-coated core tablet to provide the modified release solid oral dosage form;
wherein the modified release solid oral dosage form comprises by weight:
about 6% to about 20% of the Compound (I) or a pharmaceutically acceptable salt thereof,
about 34% to about 72% of microcrystalline cellulose,
about 5% to about 25% mannitol,
about 0% to about 20% of hydroxypropyl methyl cellulose,
about 0.5% to about 1.5% of crosslinked homopolymer of N-vinyl-2-pyrrolidone, and about 0.5% to about 1.5% of sodium stearyl fumarate;
wherein at least about 85% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer;
wherein the core composition weighs about 80% to about 91% of the total weight of the modified release solid oral dosage form;
wherein the sub-coating layer weighs about 2% to about 4% by weight of the modified release solid oral dosage form; and
wherein the enteric coating layer weighs about 6% to about 20% of the total weight of the modified release solid oral dosage form.
62 . The process of claim 61 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is a substantially pure amorphous form.